Pharmacodynamic analysis of BTK inhibition in patients with chronic lymphocytic leukemia treated with acalabrutinib

PURPOSE: To determine the pharmacodynamic relationship between target occupancy of Bruton’s tyrosine kinase (BTK) and inhibition of downstream signaling. EXPERIMENTAL DESIGN: Patients with Chronic Lymphocytic Leukemia (CLL) enrolled on a phase 2 clinical trial (NCT02337829) with the covalent, select...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Cancer Res
Prif Awduron: Alsadhan, Anfal, Cheung, Jean, Gulrajani, Michael, Gaglione, Erika M., Nierman, Pia, Hamdy, Ahmed, Izumi, Raquel, Bibikova, Elena, Patel, Priti, Sun, Clare, Covey, Todd, Herman, Sarah E. M., Wiestner, Adrian
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2020
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8301526/
https://ncbi.nlm.nih.gov/pubmed/32054731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3505
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg